- Home
- KWR vs DNLI Comparison
KWR vs DNLI Comparison
Compare KWR & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KWR | DNLI |
|---|---|---|
| Founded | 1918 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 1985 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KWR | DNLI |
|---|---|---|
| Price | $143.46 | $17.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $149.25 | $32.58 |
| AVG Volume (30 Days) | 136.7K | ★ 1.8M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,864,242,000.00 | N/A |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $4.15 | $3,993.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.08 | N/A |
| 52 Week Low | $95.91 | $10.57 |
| 52 Week High | $148.80 | $24.35 |
Technical Indicators
Market Signals| Indicator | KWR | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 48.85 |
| Support Level | $136.34 | $16.66 |
| Resistance Level | $146.16 | $18.30 |
| Average True Range (ATR) | 4.45 | 0.98 |
| MACD | 0.77 | -0.28 |
| Stochastic Oscillator | 81.78 | 21.01 |
Price Performance
Historical ComparisonAbout KWR Quaker Houghton
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.